Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer's disease: A review

Ageing Research Reviews

Volumn 27, Issue , 2016, Pages 15-22

  El Haj, Mohamad ^a   Antoine, Pascal ^a   Amouyel, Philippe ^b   Lambert, Jean Charles ^b   Pasquier, Florence ^c   Kapogiannis, Dimitrios ^d  

^a Univ Lille   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; APOE; Apolipoprotein E; Episodic memory

Indexed keywords

APOLIPOPROTEIN E4;

ALLELE; ALZHEIMER DISEASE; EMOTION; EPISODIC MEMORY; GENETIC RISK; GENOTYPE; HUMAN; INFORMATION RETRIEVAL; MEMORY; REVIEW; SAMPLE SIZE; COGNITION; GENETICS; PSYCHOLOGY;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COGNITION; HUMANS; MEMORY, EPISODIC;

EID: 84958159559     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.02.002     Document Type: Review

References (88)

1. Agosta F., Vossel K.A., Miller B.L., Migliaccio R., Bonasera S.J., Filippi M., Boxer A.L., Karydas A., Possin K.L., Gorno-Tempini M.L. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2018-2022.
2. Albert M., Smith L.A., Scherr P.A., Taylor J.O., Evans D.A., Funkenstein H.H. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci. 1991, 57:167-178.
3. Albert M., Blacker D., Moss M.B., Tanzi R., McArdle J.J. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 2007, 21:158-169.
4. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
5. Barba G.D., Nedjam Z., Dubois B. Confabulation executive functions, and source memory in Alzheimer's disease. Cogn. Neuropsychol. 1999, 16:385-398.
6. Barnett J.H., Scoriels L., Munafo M.R. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol. Psychiatry 2008, 64:137-144.
7. Belleville S., Chertkow H., Gauthier S. Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology 2007, 21:458-469.
8. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29:1943-1961.
9. Bracco L., Piccini C., Baccini M., Bessi V., Biancucci F., Nacmias B., Bagnoli S., Sorbi S. Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement. Geriatr. Cognit. Disord. 2007, 24:483-491.
10. Buschke H., Kuslansky G., Katz M., Stewart W.F., Sliwinski M.J., Eckholdt H.M., Lipton R.B. Screening for dementia with the memory impairment screen. Neurology 1999, 52:231-238.
11. Caselli R.J., Dueck A.C., Osborne D., Sabbagh M.N., Connor D.J., Ahern G.L., Baxter L.C., Rapcsak S.Z., Shi J., Woodruff B.K., Locke D.E.C., Snyder C.H., Alexander G.E., Rademakers R., Reiman E.M. Longitudinal growth modeling of cognitive aging and the APOE e4 effect. New Engl. J. Med. 2009, 361:255-263.
12. Caselli R.J., Locke D.E., Dueck A.C., Knopman D.S., Woodruff B.K., Hoffman-Snyder C., Rademakers R., Fleisher A.S., Reiman E.M. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement. 2014, 10:84-92.
13. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., Goate A.M., Bales K.R., Paul S.M., Bateman R.J., Holtzman D.M. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
14. Chang Y.L., Fennema-Notestine C., Holland D., McEvoy L.K., Stricker N.H., Salmon D.P., Dale A.M., Bondi M.W., Alzheimer's Disease Neuroimaging I. APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. Alzheimers Dement. 2014, 10:336-348.
15. Davidson Y., Gibbons L., Pritchard A., Hardicre J., Wren J., Stopford C., Julien C., Thompson J., Payton A., Pickering-Brown S.M. Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dement. Geriatr. Cognit. Disord. 2006, 23:60-66.
16. Delis D.C., Massman P.J., Butters N., Salmon D.P., Cermak L.S., Kramer J.H. Profiles of demented and amnesic patients on the California Verbal Learning iTest: implications for the assessment of memory disorders. Psychol. Assess. 1991, 3:19-26.
17. Dennis N.A., Cabeza R., Need A.C., Waters-Metenier S., Goldstein D.B., LaBar K.S. Brain-derived neurotrophic factor val66met polymorphism and hippocampal activation during episodic encoding and retrieval tasks. Hippocampus 2011, 21:980-989.
18. Diaz-Asper C.M., Goldberg T.E., Kolachana B.S., Straub R.E., Egan M.F., Weinberger D.R. Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their Siblings, and healthy controls. Biol. Psychiatry 2007.
19. Donohue M.C., Sperling R.A., Salmon D.P., Rentz D.M., Raman R., Thomas R.G., Weiner M., Aisen P.S., Australian Imaging B., Lifestyle Flagship Study of A., Alzheimer's Disease Neuroimaging I., Alzheimer's Disease Cooperative S. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014, 71:961-970.
20. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., de Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-criteria. Lancet Neurol. 2014, 13:614-629.
21. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
22. El Haj M., Allain P., Kessels R.P. The cognitive and neuroanatomical underpinnings of destination memory. Transl. Neurosci. 2014, 5:147-151.
23. El Haj M., Antoine P., Nandrino J.L., Kapogiannis D. Autobiographical memory decline in Alzheimer's disease, a theoretical and clinical overview. Ageing Res. Rev. 2015, 23:183-192.
24. El Haj M., Fasotti L., Allain P. Source monitoring in Alzheimer's disease. Brain Cogn. 2012, 80:185-191.
25. El Haj M., Kessels R.P.C. Context memory in Alzheimer's disease. Dement. Geriatr. Cognit. Disord. 2013, 3:342-350.
26. El Haj M., Moroni C., Luyat M., Omigie D., Allain P. To what extent does destination recall induce episodic reliving? Evidence from Alzheimer's disease. J. Clinic. Exp. Neuropsychol. 2014, 36:127-136.
27. Estévez-González A., García-Sánchez C., Boltes A., Otermín P., Baiget M., Escartín A., del Rio E., Gironell A., Kulisevsky J. Preclinical memory profile in Alzheimer patients with and without Allele APOE-epsilon4. Eur. Neurol. 2004, 51:199-205.
28. Ewers M., Sperling R.A., Klunk W.E., Weiner M.W., Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011, 34:430-442.
29. Fairfield B., Mammarella N. The role of cognitive operations in reality monitoring: a study with healthy older adults and Alzheimer's-type dementia. J. Gen. Psychol. 2009, 136:21-39.
30. Farrer L.A., Cupples L., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: a meta-analysis. JAMA 1997, 278:1349-1356.
31. Geroldi C., Pihlajamäki M., Laakso M.P., DeCarli C., Beltramello A., Bianchetti A., Soininen H., Trabucchi M., Frisoni G.B. APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999, 53:1825.
32. Goldman W.P., Winograd E., Goldstein F.C., O'Jile J., Green R.C. Source memory in mild to moderate Alzheimer's disease. J. Clin. Exp. Neuropsychol. 1994, 16:105-116.
33. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., Hyman B.T. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann. Neurol. 1996, 39:62-70.
34. Grober E., Buschke H. Genuine memory deficits in dementia. Dev. Neuropsychol. 1987, 3:13-36.
35. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003, 23:6690-6694.
36. Hirono N., Hashimoto M., Yasuda M., Kazui H., Mori E. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J. Neuropsychiatry Clin. Neurosci. 2003, 15:354-358.
37. Hodges J.R., Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications. Neuropsychologia 1995, 33:441-459.
38. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2892-2897.
39. Huntley J.D., Howard R.J. Working memory in early Alzheimer's disease: a neuropsychological review. Int. J. Geriatr. Psychiatry 2010, 25:121-132.
40. Huppert F.A., Brayne C., Gill C., Paykel E.S., Beardsall L. CAMCOG--concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. Br. J. Clin. Psychol. 1995, 34(Pt 4):529-541.
41. Jonker C., Schmand B., Lindeboom J., Havekes L.M., Launer L.J. Association between apolipoprotein Eε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch. Neurol. 1998, 55:1065-1069.
42. Kambeitz J.P., Bhattacharyya S., Kambeitz-Ilankovic L.M., Valli I., Collier D.A., McGuire P. Effect of BDNF val(66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci. Biobehav. Rev. 2012, 36:2165-2177.
43. Kantarci K., Lowe V., Przybelski S.A., Weigand S.D., Senjem M.L., Ivnik R.J., Preboske G.M., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012, 78:232-240.
44. Keenan B.T., Shulman J.M., Chibnik L.B., Raj T., Tran D., Sabuncu M.R., Allen A.N., Corneveaux J.J., Hardy J.A., Huentelman M.J., Lemere C.A., Myers A.J., Nicholson-Weller A., Reiman E.M., Evans D.A., Bennett D.A., De Jager P.L. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum. Mol. Genet. 2012, 21:2377-2388.
45. Kleiman T., Zdanys K., Black B., Rightmer T., Grey M., Garman K., MacAvoy M., Gelernter J., van Dyck C. Apolipoprotein E 4 Allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement. Geriatr. Cognit. Disord. 2006, 22:73-82.
46. Lambert J.C., Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis?. Curr. Opin. Genet. Dev. 2011, 21:295-301.
47. Lange K.L., Bondi M.W., Salmon D.P., Galasko D., Delis D.C., Thomas R.G., Thal L.J. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J. Int. Neuropsychol. Soc. 2002, 8:943-955.
48. Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Helkala E.L., Hartikainen P., Hanninen T., Ryynanen M., Riekkinen P.J. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996, 46:413-419.
49. Lim Y.Y., Villemagne V.L., Laws S.M., Pietrzak R.H., Snyder P.J., Ames D., Ellis K.A., Harrington K., Rembach A., Martins R.N., Rowe C.C., Masters C.L., Maruff P. APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. Mol. Psychiatry 2014.
50. Lindeboom J., Schmand B., Tulner L., Walstra G., Jonker C. Visual association test to detect early dementia of the Alzheimer type. J. Neurol. Neurosurg. Psychiatry 2002, 73:126-133.
51. Luczywek E., Nowicka A., Pfeffer A., Czyzewski K., Styczynska M., Lalowski M., Barcikowska M. Cognitive deficits and polymorphism of apolipoprotein E in Alzheimer's disease. Dement. Geriatr. Cognit. Disord. 2002, 13:171-177.
52. Mardh S., Nagga K., Samuelsson S. A longitudinal study of semantic memory impairment in patients with Alzheimer's disease. Cortex 2013, 49:528-533.
53. Marra C., Bizzarro A., Daniele A., De Luca L., Ferraccioli M., Valenza A., Brahe C., Tiziano F.D., Gainotti G., Masullo C. Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement. Geriatr. Cognit. Disord. 2004, 18:125-131.
54. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
55. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
56. Mohs R.C., Rosen W.G., Davis K.L. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol. Bull. 1983, 19:448-450.
57. Mormino E.C., Betensky R.A., Hedden T., Schultz A.P., Ward A., Huijbers W., Rentz D.M., Johnson K.A., Sperling R.A., Alzheimer's Disease Neuroimaging I., Australian Imaging B., Lifestyle Flagship Study of A., Harvard Aging Brain S. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014, 82:1760-1767.
58. Multhaup K.S., Balota D.A. Generation effects and source memory in healthy older adults and in adults with dementia of the Alzheimer type. Neuropsychology 1997, 11:382-391.
59. Nagy Z., Esiri M.M., Jobst K.A., Johnston C., Litchfield S., Sim E., Smith A.D. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995, 69:757-761.
60. Pennanen C., Kivipelto M., Tuomainen S., Hartikainen P., Hanninen T., Laakso M.P., Hallikainen M., Vanhanen M., Nissinen A., Helkala E.L., Vainio P., Vanninen R., Partanen K., Soininen H. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol. Aging 2004, 25:303-310.
61. Pietrzak R.H., Lim Y.Y., Ames D., Harrington K., Restrepo C., Martins R.N., Rembach A., Laws S.M., Masters C.L., Villemagne V.L., Rowe C.C., Maruff P., Australian Imaging B., Lifestyle Research G. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol. Aging 2015, 36:1231-1238.
62. Pievani M., Rasser P.E., Galluzzi S., Benussi L., Ghidoni R., Sabattoli F., Bonetti M., Binetti G., Thompson P.M., Frisoni G.B. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 2009, 45:1090-1098.
63. Piolino P., Desgranges B., Belliard S., Matuszewski V., Lalevee C., De la Sayette V., Eustache F. Autobiographical memory and autonoetic consciousness: triple dissociation in neurodegenerative diseases. Brain 2003, 126:2203-2219.
64. Praetorius M., Thorvaldsson V., Hassing L.B., Johansson B. Substantial effects of apolipoprotein E epsilon4 on memory decline in very old age: longitudinal findings from a population-based sample. Neurobiol. Aging 2013, 34:2734-2739.
65. Rauchs G., Piolino P., Mézenge F., Landeau B., Lalevée C., Pélerin A., Viader F., De La Sayette V., Eustache F., Desgranges B. Autonoetic consciousness in Alzheimer's disease: neuropsychological and PET findings using an episodic learning and recognition task. Neurobiol. Aging 2007, 28:1410-1420.
66. Remy F., Mirrashed F., Campbell B., Richter W. Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study. Neuroimage 2005, 25:253-266.
67. Resnick S.M., Bilgel M., Moghekar A., An Y., Cai Q., Wang M.C., Thambisetty M., Prince J.L., Zhou Y., Soldan A., Wong D.F., O'Brien R.J., Ferrucci L., Albert M.S. Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol. Aging 2015, 36:2333-2339.
68. Risacher S.L., Kim S., Shen L., Nho K., Foroud T., Green R.C., Petersen R.C., Jack C.R., Aisen P.S., Koeppe R.A., Jagust W.J., Shaw L.M., Trojanowski J.Q., Weiner M.W., Saykin A.J., Alzheimer's Disease Neuroimaging Initiative d The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI), Front. Aging Neurosci. 2013, 5:11.
69. Rey A. L'examen Clinique en Psychologie 1958, Presses Universitaires de France, Paris.
70. Russell E.W. A multiple scoring method for the assessment of complex memory functions. J. Consult. Clin. Psychol. 1975, 43:800-809.
71. Savitz J., Solms M., Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Behav. 2006, 5:311-328.
72. Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
73. Small B.J., Rosnick C.B., Fratiglioni L., Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 2004, 19:592-600.
74. Smith G.E., Bohac D.L., Waring S.C., Kokmen E., Tangalos E.G., Ivnik R.J., Petersen R.C. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 1998, 50:355-362.
75. Snowden J.S., Stopford C.L., Julien C.L., Thompson J.C., Davidson Y., Gibbons L., Pritchard A., Lendon C.L., Richardson A.M., Varma A., Neary D., Mann D. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007, 43:835-845.
76. Sutphen C.L., Jasielec M.S., Shah A.R., Macy E.M., Xiong C., Vlassenko A.G., Benzinger T.L., Stoops E.E., Vanderstichele H.M., Brix B., Darby H.D., Vandijck M.L., Ladenson J.H., Morris J.C., Holtzman D.M., Fagan A.M. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015, 72:1029-1042.
77. Sweet R.A., Seltman H., Emanuel J.E., Lopez O.L., Becker J.T., Bis J.C., Weamer E.A., DeMichele-Sweet M.A., Kuller L.H. Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am. J. Psychiatry 2012, 169:954-962.
78. Tapia-Arancibia L., Aliaga E., Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res. Rev. 2008, 59:201-220.
79. Thorvaldsson V., Nordlund A., Reinvang I., Blennow K., Zetterberg H., Wallin A., Johansson B. Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42. Int. Psychogeriatr. / IPA 2010, 22:598-606.
80. Tromp D., Dufour A., Lithfous S., Pebayle T., Despres O. Episodic memory in normal aging and Alzheimer disease: insights from imaging and behavioral studies. Ageing Res. Rev. 2015, 24:232-262.
81. Tulving E. Episodic memory: from mind to brain. Annu. Rev. Psychol. 2002, 53:1-25.
82. van der Flier W.M., Schoonenboom S.N., Pijnenburg Y.A., Fox N.C., Scheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006, 67:526-527.
83. van der Vlies A.E., Pijnenburg Y.A.L., Koene T., Klein M., Kok A., Scheltens P., van der Flier W.M. Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement. Geriatr. Cognit. Disord. 2007, 24:98-103.
84. Wechsler D. A Standardized memory scale for clinical use. J. Psychol. 1945, 19:87-95.
85. Wilson R.S., Schneider J.A., Barnes L.L., Beckett L.A., Aggarwal N.T., Cochran E.J., Berry-Kravis E., Bach J., Fox J.H., Evans D.A., Bennett D.A. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch. Neurol. 2002, 59:1154-1160.
86. Wisdom N.M., Callahan J.L., Hawkins K.A. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol. Aging 2011, 32:63-74.
87. Wolk D.A., Dickerson B.C., Alzheimer's Disease Neuroimaging I. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10256-10261.
88. Yavich L., Forsberg M.M., Karayiorgou M., Gogos J.A., Mannisto P.T. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci. 2007, 27:10196-10209.